Rapport Therapeutics, Inc. (RAPP)
Nasdaq · Healthcare · Biotechnology
$32.19+0.06%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $1.5B
- 52-week range
- $23.75 – $52.93
- 52-week change
- +21.75%
- EPS (trailing)
- −$3.03
- Analyst rating
- 1.1 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Net income
- −$111M
- Diluted EPS
- −$2.86
- Free cash flow
- −$88.1M
From the company’s annual report on SEC EDGAR.
About Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
Headquarters: Boston, United States · 84 employees · rapportrx.com